MDT

83.91

+1.1%↑

VEEV

217.05

+2.03%↑

A

105.21

+1.88%↑

HQY

81.15

+1.69%↑

PDCO

31.07

+0.55%↑

MDT

83.91

+1.1%↑

VEEV

217.05

+2.03%↑

A

105.21

+1.88%↑

HQY

81.15

+1.69%↑

PDCO

31.07

+0.55%↑

MDT

83.91

+1.1%↑

VEEV

217.05

+2.03%↑

A

105.21

+1.88%↑

HQY

81.15

+1.69%↑

PDCO

31.07

+0.55%↑

MDT

83.91

+1.1%↑

VEEV

217.05

+2.03%↑

A

105.21

+1.88%↑

HQY

81.15

+1.69%↑

PDCO

31.07

+0.55%↑

MDT

83.91

+1.1%↑

VEEV

217.05

+2.03%↑

A

105.21

+1.88%↑

HQY

81.15

+1.69%↑

PDCO

31.07

+0.55%↑

Search

Apellis Pharmaceuticals Inc

Open

SectorGezondheidszorg

19.95 4.12

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.76

Max

20.16

Belangrijke statistieken

By Trading Economics

Inkomsten

21M

-36M

Verkoop

16M

213M

EPS

-0.29

Winstmarge

-17.105

Werknemers

705

EBITDA

20M

-24M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+111.72% upside

Dividenden

By Dow Jones

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-563M

2.8B

Vorige openingsprijs

15.83

Vorige sluitingsprijs

19.95

Nieuwssentiment

By Acuity

69%

31%

355 / 386 Rangschikking in Healthcare

Apellis Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 apr 2025, 23:56 UTC

Top Nieuws

Australian Consumer Confidence Firms Despite Market Falls

7 apr 2025, 23:45 UTC

Populaire aandelen

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

7 apr 2025, 21:36 UTC

Belangrijke Marktbewegers

Medicare Insurer Shares Rise on Plans for Higher Payment Rates

7 apr 2025, 21:11 UTC

Belangrijke Marktbewegers

Broadcom Authorizes $10 Billion Share Repurchase Program

7 apr 2025, 23:48 UTC

Marktinformatie

Nikkei May Rise After Recent Selloffs -- Market Talk

7 apr 2025, 23:47 UTC

Marktinformatie

Gold Edges Lower Amid More Cautious Near-Term Outlook -- Market Talk

7 apr 2025, 23:34 UTC

Top Nieuws

Apple Users Rush to Upgrade iPhones Ahead of Potential Tariffs-Related Price Hikes -- WSJ

7 apr 2025, 22:18 UTC

Top Nieuws

Health Insurer Stocks Jump After Medicare Boosts Payment Rates -- Barrons.com

7 apr 2025, 21:43 UTC

Marktinformatie

Oil Producers Choosing Returns Over Growth In Tariffs Fallout -- Market Talk

7 apr 2025, 21:37 UTC

Marktinformatie

Canada Faces Financial Crisis-Like Symptoms That Rate Cuts Won't Cure -- Market Talk

7 apr 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Infineon: All-Cash Transaction to Be Financed From Existing Liquidity and Additional Debt >IFX.FF

7 apr 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Infineon: Transaction Combines Infineon's Portfolio for Automotive Microcontrollers With Automotive Ethernet Business of Marvell, Accelerating Infineon's System Capabilities for Software-Defined Vehicles >IFX.FF

7 apr 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Infineon: Business Expected to Generate Rev of $225M-$250M in Calendar Yr 2025 With Gross Margin of Around 60% >IFX.FF

7 apr 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Infineon: Enters Agreement for Acquisition of Marvell Technology's Automotive Ethernet Business for US$2.5 B >IFX.FF

7 apr 2025, 21:31 UTC

Top Nieuws

Apple Plans to Source More iPhones From India as Potential Tariff Fix -- Update

7 apr 2025, 21:29 UTC

Top Nieuws

PNC Names Former BlackRock Star Mark Wiedman as President -- WSJ

7 apr 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Infineon Further Strengthens Its Number One Position In Automotive Microcontrollers And Boosts Systems Capabilities For Software-defined Vehicles With Acquisition Of Marvell's Automotive Ethernet Business >IFNNY MRVL

7 apr 2025, 21:21 UTC

Top Nieuws

Defense Stocks Can't Escape the Trade War. Expect to Hear This Term. -- Barrons.com

7 apr 2025, 21:18 UTC

Top Nieuws
Winsten

Levi Strauss Trying to Mitigate Tariff Impact on Consumer; Company Grows Revenue -- Update

7 apr 2025, 21:17 UTC

Winsten

Levi Sees U.S. Consumer 'Generally Resilient,' CFO Says

7 apr 2025, 21:17 UTC

Winsten

Levi Looking at Cost-Related Opportunities, Pricing Changes as Part of Response, CFO Says

7 apr 2025, 21:16 UTC

Winsten

Levi Strauss Sets Up Task Force to Understand Implications of Trump's Tariffs, CFO Singh Says

7 apr 2025, 21:16 UTC

Top Nieuws

What to Know About Trump's Latest Tariffs -- 3rd Update

7 apr 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Marvell to Sell In-Vehicle Network Portfolio for $2.5B

7 apr 2025, 21:14 UTC

Top Nieuws

PNC Taps Ex-BlackRock Star Mark Wiedman as President -- WSJ

7 apr 2025, 21:06 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Trump Orders New Review of Nippon-U.S. Steel Merger -- 3rd Update

7 apr 2025, 21:03 UTC

Top Nieuws

Even Google Could Feel the Sting of a Trade War -- Barrons.com

7 apr 2025, 20:59 UTC

Top Nieuws

U.S. Stock Meltdown Gives Way to Global Rout -- WSJ

7 apr 2025, 20:56 UTC

Belangrijke Marktbewegers

Broadcom Authorizes $10B Share Repurchase Program

7 apr 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Apellis Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

111.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 42.28 USD  111.72%

Hoogste 75 USD

Laagste 24 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Apellis Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

20 ratings

12

Buy

8

Hold

0

Sell

Sentiment

By Acuity

355 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.